论文信息 - Phase I trial of intermittent administration of sorafenib (BAY 43–9006) for patients (pts) with refractory/relapsed acute myelogenous leukemia (AML) - 字舞流文

Phase I trial of intermittent administration of sorafenib (BAY 43–9006) for patients (pts) with refractory/relapsed acute myelogenous leukemia (AML)

M. Konopleva | H. Kantarjian | J. Cortes | S. Verstovsek | M. Andreef | G. Borthakur | J. Wright | S. Faderl | Wenyong Zhang | A. Quintás-Cardama